Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ricolinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 known ✓ | Q9UBN7 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 5/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 4/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 4/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 3/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21707466 | 0.99 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL28085707 | 0.92 | HDAC6 (0.84) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL21943234 | 0.91 | HDAC6 (0.83) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| Citarinostat SCHEMBL2225863 | 0.91 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL18347205 | 0.91 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL2226158 | 0.91 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| Citarinostat SCHEMBL29882816 | 0.91 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL2225424 | 0.90 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL2226917 | 0.90 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL10050271 | 0.90 | HDAC6 (0.81) | HDAC6HDAC1HDAC3HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2341 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070932-A | Application of combination of decitabine and anti-HER 2 antibody in preparation of medicines for treating tumors | 上海交通大学 | 2026-05-22 | — | — | CN | claimed |
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-3429570-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | ORYZON GENOMICS SA (ES) | 2026-05-20 | — | — | EP | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108514-A1 | METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-04-23 | — | — | US | claimed |
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | claimed |
| EP-4684836-A2 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Oryzon Genomics, S.A. (ES) | 2026-01-28 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| WO-2025227007-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-30 | — | — | WO | claimed |
| US-9512083-B2 | Histone deacetylase 6 selective inhibitors for the treatment of bone disease | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-06 | — | — | US | claimed |
| EP-3091004-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | Acetylon Pharmaceuticals, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| WO-2016120432-A1 | COMPOUNDS AND METHODS FOR ANTICOAGULATION THERAPY | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-08-04 | — | — | WO | claimed |
| CN-105753739-A | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | 埃斯泰隆制药公司 | 2016-07-13 | — | — | CN | claimed |
| WO-2016030345-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-03-03 | — | — | WO | claimed |
| US-20140378385-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-25 | — | — | US | claimed |
| EP-2734500-A2 | HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE | The General Hospital Corporation (US) | 2014-05-28 | — | — | EP | claimed |
| WO-2013013113-A2 | HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | WO | claimed |
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | claimed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | claimed |